Abstract
Half a century after its discovery, hepatitis delta remains a pertinent global health issue with a major clinical impact in endemic regions and an underestimated prevalence worldwide. Hepatitis delta virus infection follows a challenging clinical course and is responsible for significant liver-related morbidity. Although the only currently available treatment (pegylated interferon) does not provide consistent results, emerging therapeutic options are promising. This article explores the epidemiology, natural history, as well as current and potential therapeutic options for hepatitis delta virus infection.
Keywords:
Chronic liver disease; Hepatitis B; Hepatitis D; Investigational treatments.
Published by Elsevier Inc.
MeSH terms
-
Adenine / analogs & derivatives
-
Adenine / therapeutic use
-
Antibodies, Viral / blood
-
Antiviral Agents / therapeutic use
-
Biomarkers / blood
-
Carcinoma, Hepatocellular / etiology
-
Global Health
-
Hepatitis D / diagnosis*
-
Hepatitis D / epidemiology
-
Hepatitis D / therapy*
-
Hepatitis D / virology
-
Hepatitis Delta Virus / genetics
-
Hepatitis Delta Virus / immunology
-
Hepatitis delta Antigens / immunology
-
Humans
-
Interferon alpha-2 / therapeutic use
-
Lamivudine / therapeutic use
-
Liver Cirrhosis / etiology
-
Liver Neoplasms / etiology
-
Liver Transplantation
-
Organophosphonates / therapeutic use
-
Prevalence
-
RNA, Viral
-
Risk
-
Serologic Tests / methods
Substances
-
Antibodies, Viral
-
Antiviral Agents
-
Biomarkers
-
Hepatitis delta Antigens
-
Interferon alpha-2
-
Organophosphonates
-
RNA, Viral
-
Lamivudine
-
adefovir
-
Adenine